Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of subcutaneous versus intravenous fixed-dose nivolumab + relatlimab in previously untreated unresectable or metastatic melanoma
MOH_2023-06-13_012205Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, relatlimab and ENHANZE in melanoma (2 arms), sponsored by Bristol Myers Squibb. Started Apr 2023; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2023-06-13_012205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-13_012205.